Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Cytokinetics Inc (NASDAQ: CYTK) closed at $60.82 in the last session, up 1.08% from day before closing price of $60.17. In other words, the price has increased by $1.08 from its previous closing price. On the day, 1.66 million shares were traded. CYTK stock price reached its highest trading level at $61.48 during the session, while it also had its lowest trading level at $59.64.
Ratios:
We take a closer look at CYTK’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.76 and its Current Ratio is at 6.76.
On April 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $55.
On February 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $86.Citigroup initiated its Buy rating on February 07, 2025, with a $86 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 07 ’25 when Malik Fady Ibraham sold 2,000 shares for $60.56 per share. The transaction valued at 121,120 led to the insider holds 140,610 shares of the business.
Kaye Edward M. MD sold 6,757 shares of CYTK for $405,420 on Oct 06 ’25. The Director now owns 9,778 shares after completing the transaction at $60.00 per share. On Oct 06 ’25, another insider, EDWARD KAYE, who serves as the Director of the company, bought 6,757 shares for $56.97 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 7277548032 and an Enterprise Value of 7411171328. For the stock, the TTM Price-to-Sale (P/S) ratio is 84.88. Its current Enterprise Value per Revenue stands at 86.44 whereas that against EBITDA is -13.786.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.57, which has changed by 0.14430857 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $61.19, while it has fallen to a 52-week low of $29.31. The 50-Day Moving Average of the stock is 34.81%, while the 200-Day Moving Average is calculated to be 46.83%.
Shares Statistics:
According to the various share statistics, CYTK traded on average about 2.15M shares per day over the past 3-months and 2247600 shares per day over the past 10 days. A total of 119.60M shares are outstanding, with a floating share count of 117.03M. Insiders hold about 2.19% of the company’s shares, while institutions hold 114.22% stake in the company. Shares short for CYTK as of 1757894400 were 14257043 with a Short Ratio of 6.62, compared to 1755216000 on 15325098. Therefore, it implies a Short% of Shares Outstanding of 14257043 and a Short% of Float of 15.529999.
Earnings Estimates
The stock of Cytokinetics Inc (CYTK) is currently being evaluated by 16.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$1.57, with high estimates of -$1.21 and low estimates of -$2.06.
Analysts are recommending an EPS of between -$4.95 and -$6.3 for the fiscal current year, implying an average EPS of -$5.62. EPS for the following year is -$5.73, with 14.0 analysts recommending between -$4.09 and -$7.21.
Revenue Estimates
A total of 19 analysts have provided revenue estimates for CYTK’s current fiscal year. The highest revenue estimate was $153.83M, while the lowest revenue estimate was $68.3M, resulting in an average revenue estimate of $83.58M. In the same quarter a year ago, actual revenue was $18.47MBased on 17 analysts’ estimates, the company’s revenue will be $148.66M in the next fiscal year. The high estimate is $402M and the low estimate is $33.9M.
